Taysha Expands Age Eligibility for Canadian Clinical Trial

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

Donate

Join Us

Taysha Gene Therapies reports on safety and efficacy results for the first patient to receive gene therapy for Rett Syndrome

On November 29, 2023 Taysha Gene Therapies announced that Health Canada has authorized a protocol amendment to the ongoing REVEAL Phase 1/2 adult trial evaluating TSHA-102 that expands eligibility to include patients aged 12 and older with Rett syndrome.

Taysha Press Release

$40M

Take Action